Researchers from UH Seidman Cancer Center will present data on a new online tool for estimating individualized survival probabilities in patients with newly diagnosed glioblastoma. The studies also explore promising new treatments, including pembrolizumab for head and neck squamous cell carcinoma, and improve patient participation in c...
The Society of Surgical Oncology and European Society of Surgical Oncology propose a global curriculum to address training variations and inadequacies. The curriculum aims to create a robust workforce of well-trained surgical oncologists to meet the growing need resulting from the rising global cancer burden.
The demand for radiotherapy is expected to increase by 16% between 2012 and 2025, with prostate cancer cases projected to rise by 24%. This is due to an aging population in Europe, with four million new cancer patients expected in 2025. The study's authors aim to help policymakers plan for increased radiotherapy services.
Suresh Senan, a renowned expert in radiation oncology, has been awarded the Heine H. Hansen Award for his pioneering work in lung cancer therapy and research. The award recognizes his significant contributions to the field of lung cancer on an international basis.
A clinical trial confirms that a shortened radiotherapy schedule is as effective as conventional radiotherapy in treating low-risk prostate cancer patients. Patients treated with the shorter regimen experienced more mild side effects, but no difference in severe late side effects.
Patients with grade 2 glioma who received combined chemotherapy and radiation therapy experienced longer progression-free survival and overall survival compared to those who received radiation therapy alone. The study's findings suggest that initial therapy of RT followed by PCV is necessary to achieve longer survival.
A new study published in the American Journal of Clinical Oncology found that increasing radiation doses for patients with non-metastatic prostate cancer does not improve long-term outcomes. The study analyzed data from 12 randomized controlled trials and found no association between higher doses and improved survival rates.
The Memorial Sloan Kettering Cancer Center fellowship program successfully trains international surgeons to return home and perform cancer operations, addressing a significant gap in low- and middle-income countries.
Physician-scientists Ethan Dmitrovsky and Waun Ki Hong recognized for their efforts in cancer prevention and control. Dmitrovsky's work on retinoids has led to a significant impact on leukemia treatment, while Hong's research in cancer chemoprevention and personalized therapies has advanced the field.
Researchers at Thomas Jefferson University found that combining radiotherapy with the drug panobinostat improved progression-free survival and overall survival for patients with high-grade gliomas. The study, published online ahead of print in the Journal of Neuro-Oncology, offers promise for a new treatment approach.
A study published in Circulation found that prostate cancer survivors are at higher risk of developing cardiovascular disease due to hormone therapy. The Vanderbilt Cardio-oncology program is working to modulate these risks through collaborative care and personalized interventions.
The International Radiosurgery Oncology Consortium has developed consensus guidelines for the safe implementation and practice of Stereotactic Body Radiation Therapy (SBRT) for primary renal cell carcinoma. SBRT is a non-invasive treatment option with favorable comparisons to existing treatments, offering a cost-effective and widely av...
Researchers from the Repurposing Drugs in Oncology project have found that diclofenac, a common painkiller, has significant anti-cancer properties. The study suggests that existing non-cancer drugs may represent a valuable source of novel therapies for cancer treatment.
The new oral drug Palbociclib has shown promise in combating various types of cancer beyond breast cancer, including lymphoma, sarcoma, and teratoma. Early trials have demonstrated its effectiveness in slowing tumor growth and improving survival rates in patients with these conditions.
The Journal of Comparative Effectiveness Research discusses new recommendations from the Center for Medical Technology Policy's Green Park Collaborative for evaluating oncology treatment sequences. The framework developed by GPC-USA aims to fill evidence gaps and identify patient-important outcomes, ultimately improving cancer patient ...
Dr. Norman Wolmark will present the William L. McGuire Memorial Lecture on the NSABP Clinical Trials' impact on early breast cancer management. Established in 1992, the McGuire Lectureship commemorates Dr. William McGuire's contributions to oncology.
A study of medical records found that men taking androgen deprivation therapy for prostate cancer were almost twice as likely to be diagnosed with Alzheimer's disease as those who didn't undergo the therapy. The longer duration of ADT, the greater the risk of Alzheimer's disease.
A new template published by ASTRO streamlines post-treatment care for cancer survivors, facilitating consistency and reducing provider burden. The template includes elements required by CoC accreditation requirements, coordinating care among primary care providers, radiation specialists, and patients.
Researchers at IRCM identified the mechanism of action for a new target in immune-oncology treatments, focusing on natural killer cells and DNAM-1 protein. The discovery could lead to improved therapies using antibodies against TIGIT receptor.
The Integrated Mathematical Oncology Department at Moffitt Cancer Center has been awarded a $10.4 million grant from the National Cancer Institute to develop new strategies to prevent and treat cancer by exploiting Charles Darwin's concept of natural selection.
A study found that low BRCA1 protein expression in glioblastoma tumors correlates with longer overall survival, suggesting a potential predictive biomarker for treatment responses to DNA-damaging therapies.
The NRG Oncology/RTOG 0813 trial found SBRT to be well-tolerated in early-stage, centrally located non-small cell lung cancer patients. The highest dose level allowed by the protocol was reached without significant toxicity.
New data from clinical trials at Penn Medicine demonstrate the clinical benefits of proton therapy for patients with advanced lung, pancreatic, and spine cancers. Proton therapy has been shown to reduce toxicities and improve survival rates compared to conventional radiation therapy.
A shortened radiotherapy schedule has been shown to have similar efficacy as a conventional course in treating low-risk prostate cancer. The study found that patients treated with the shorter schedule experienced no significant decrease in cancer control compared to those treated with the longer conventional schedule.
The RTOG 9601 study found that adding anti-androgen therapy to salvage radiotherapy improved overall survival and reduced prostate cancer death. The treatment also showed no significant increase in radiation toxicity.
The International Association for the Study of Lung Cancer (IASLC) has appointed Elsevier as the new publisher of its official journal, Journal of Thoracic Oncology. This partnership aims to enhance the journal's reputation and influence while expanding its global communities of contributors and readers.
The journal published a Special Focus issue documenting advancements in oncology since its debut in 2005. Review articles cover topics such as immunotherapy and stereotactic body radiotherapy, providing insights into the latest scientific and clinical issues in cancer research.
The ESMO Global Opioid Policy Initiative reveals disparities in opioid access across the globe, with the Middle East, Latin America, and Asia showing limited access to essential pain relieving medication. The addition of new Designated Centres brings polices tailored to patient needs, promoting a multidisciplinary approach to cancer care.
A new report highlights progress in treating childhood cancers, but notes that many survivors face long-term treatment-related side effects. The European Society for Paediatric Oncology proposes solutions to tackle these issues, including improving access to new drugs and enhancing collaboration with adult oncology.
The Montefiore-Einstein Center for Cancer Care has received a $3.93 million grant from the National Cancer Institute to support clinical oncology research. Four new scholars have been selected, including Drs. Thomas Ow and Akiva Novetsky, who will focus on radiation therapy and gynecologic oncology surgeries.
The American Society for Radiation Oncology (ASTRO) has awarded a total of $33,500 to 41 researchers for their outstanding contributions to the field of radiation oncology. The awards recognize top-rated abstracts presented at the 2015 Annual Meeting, with recipients receiving cash honors and complimentary registration.
Researchers create economic model to assess life expectancy, management of adverse effects, and quality of life for new oncology drugs like necitumumab. The study finds that the value-based price for necitumumab ranges between $563 and $1,309 per three-week cycle.
The American Society for Radiation Oncology has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. The recipients will support studies in radiation and cancer biology, as well as outcomes/health services research within radiation oncology.
The ESMO Women for Oncology Task Force aims to address inequalities among women oncologists, and the new award will be presented to Enriqueta Felip, who kick-started awareness of the lack of women oncologists in leadership roles. The award recognizes contributors who support the development of women in oncology.
A recent study published in the Journal of Geriatric Oncology found that 26% of senior oncology patients use complementary or alternative medicines, which can interact with cancer treatments. The study highlights the need for comprehensive screening and documentation of CAM use in older cancer patients.
The European Society for Medical Oncology (ESMO) announced the award of its esteemed prizes to three exceptional medical oncologists: Nathan Cherny, Nagahiro Saijo, and Cornelis Punt. These pioneers have made groundbreaking contributions to palliative care integration, medical oncology in Asia, and immunotherapy approaches.
Women with early-stage breast cancer who receive a shorter course of whole breast radiation therapy experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment. The study suggests that hypofractionated treatment should be considered as a starting point for discussion between patients...
BMJ has partnered with the European Society for Medical Oncology (ESMO) to publish a new open access cancer journal called ESMO Open. The journal will cover various aspects of cancer treatment and include study protocols and phase I clinical trials. It aims to provide rapid access to high-quality research on cancer care worldwide.
A study published in JAMA Oncology found that chemotherapy was associated with worse quality of life near death for patients who could still perform many life functions. The researchers concluded that chemotherapy use may be unnecessary and potentially harmful for patients with progressive metastatic disease.
A large trial shows liquid biopsy (BEAMing technology) detects tumor genotypes not found in tissue biopsies, enabling targeted therapy selection. Regorafenib benefits patients with KRAS and PIK3CA mutations, revolutionizing colorectal cancer treatment.
A study of 76 patients with cervical or endometrial cancer found that extended-field IMRT did not increase duodenal toxicity risk, even at high doses. The study confirms the safety of EF-IMRT for treating para-aortic lymph nodes.
The American Society for Radiation Oncology (ASTRO) has launched a new open-access journal, Advances in Radiation Oncology, with Founding Editor Robert C. Miller, M.D. The journal will publish original research on novel retrospectives and hypothesis-generating series, with a focus on practice transformation.
Dr. Maurizio D'Incalci receives the first Pezcoller-Prodi Award in recognition of his work on translational cancer research and therapeutic oncology. The award highlights his contributions to the development of novel anticancer drugs, including trabectedin.
The American College of Cardiology seeks to expand cardio-oncology services to address the growing need for specialized care in cardiovascular health for cancer patients. Currently, many hospital training programs lack formal training or services in this area, and a nationwide survey reveals gaps in resources and best practices.
The newly redesigned Oncology Central is now live, featuring a dedicated Pipelines and Trials section, webinars, and exclusive multimedia content. The platform offers easy navigation and access to peer-reviewed journal articles, regular cancer news updates, and exciting features.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
The American Society for Radiation Oncology (ASTRO) has issued a new guideline on definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer, citing 35 years of data to guide current treatment and future research. The guideline recommends RT as the ideal treatment for patients with locally advanced NSCLC.
The Global Cancer Project Map is an online resource connecting the global cancer community, enabling access to cancer projects and expertise. The map covers a range of projects, from prevention to palliative care, and aims to reduce health disparities and strengthen human capital in underserved areas.
The International Lymphoma Radiation Oncology Group (ILROG) has issued a guideline outlining the use of 3D computed tomography-based radiation therapy planning and volumetric image guidance to treat pediatric Hodgkin lymphoma. The guidelines aim to reduce radiation dose to normal tissue and decrease the risk of late side effects.
A study in Lancet Oncology suggests continued treatment with YONDELIS for advanced soft-tissue sarcoma patients who have not progressed after six courses improves progression-free survival. The results also indicate that a drug holiday may worsen outcomes.
A new standard of care for soft tissue sarcomas has been established through a study that shows image-guided radiotherapy can reduce long-term side effects while maintaining survival rates. The treatment delivers smaller radiation doses to tumors, minimizing exposure to surrounding healthy tissue.
The American Society of Clinical Oncology (ASCO) announces its cancer Advance of the Year, four new treatments improving outlook for patients with chronic lymphocytic leukemia (CLL). New therapies include immunotherapy drugs and molecularly targeted drugs offering more effective treatment options.
A 2013 survey of radiation oncologists found that peer review is a common practice in medicine, but there is wide variation in its performance. Seventy-eight percent of respondents reported being involved in peer review, and 74% expressed interest in formal guidelines to improve the process.
Neoplasia and Translational Oncology, two leading open-access cancer research journals, are now published by Elsevier. These peer-reviewed journals feature studies on novel investigations in oncology research, providing important data for advancing cancer diagnosis and treatment.
A new study published in the Journal of Clinical Oncology found that the risk of developing leukemia after radiation therapy or chemotherapy for early-stage breast cancer is twice as high as previously reported. The study analyzed data from 20,063 breast cancer patients and found a cumulative risk of 0.5 percent.
A study by Ohio State University researchers found that patients treated at highly-experienced radiation oncology centers had better survival rates and fewer cancer recurrences compared to those treated at less experienced centers. The study analyzed data from 470 patients treated with radiation therapy between 2002-2005.
A study by Ben-Gurion University of the Negev found that preclinical oncology courses increased students' interest in specializing in oncology and empathy for cancer patients. The research suggests a need for medical schools to include such curriculum to develop communication skills and sensitivity towards death and dying.
A study analyzing Medicare claims found that biopsies accounted for 43.1% of $38.3 million in diagnostic costs for patients with ultimately negative lung cancer diagnoses. Lung biopsies were also the most expensive test, with a median cost of $3,784 and an average cost including complications of $37,745.
Research shows that primary care providers who know guideline recommendations for low-dose computed tomography (LDCT) screening are more likely to order LDCT for high-risk individuals. This knowledge gap is highlighted by a survey of over 200 primary care providers, which found that 48% knew three or more guideline components.